Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 13, 2023

Regorafenib Monotherapy as Second-Line Treatment for RAS-Mutant Advanced Colorectal Cancer



Additional Info

Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study
ESMO Open 2023 Jan 03;8(1)100748, C Cardone, A De Stefano, G Rosati, A Cassata, L Silvestro, M Borrelli, E Di Gennaro, C Romano, A Nappi, N Zanaletti, F Foschini, R Casaretti, F Tatangelo, S Lastoria, M Raddi, D Bilancia, V Granata, S Setola, A Petrillo, C Vitagliano, P Gargiulo, L Arenare, A Febbraro, E Martinelli, F Ciardiello, P Delrio, A Budillon, MC Piccirillo, A Avallone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading